• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

协作综述:影响局限性肾实体瘤患者治疗决策的因素。

Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass.

机构信息

Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

Department of Urology, Mayo Clinic, Rochester, NY, USA.

出版信息

Eur Urol. 2021 Nov;80(5):575-588. doi: 10.1016/j.eururo.2021.01.021. Epub 2021 Feb 6.

DOI:10.1016/j.eururo.2021.01.021
PMID:33558091
Abstract

CONTEXT

With the addition of active surveillance and thermal ablation (TA) to the urologist's established repertoire of partial (PN) and radical nephrectomy (RN) as first-line management options for localized renal cell carcinoma (RCC), appropriate treatment decision-making has become increasingly nuanced.

OBJECTIVE

To critically review the treatment options for localized, nonrecurrent RCC; to highlight the patient, renal function, tumor, and provider factors that influence treatment decisions; and to provide a framework to conceptualize that decision-making process.

EVIDENCE ACQUISITION

A collaborative critical review of the medical literature was conducted.

EVIDENCE SYNTHESIS

We identify three key decision points when managing localized RCC: (1) decision for surveillance versus treatment, (2) decision regarding treatment modality (TA, PN, or RN), and (3) decision on surgical approach (open vs minimally invasive). In evaluating factors that influence these treatment decisions, we elaborate on patient, renal function, tumor, and provider factors that either directly or indirectly impact each decision point. As current nomograms, based on preselected patient datasets, perform poorly in prospective settings, these tools should be used with caution. Patient decision aids are an underutilized tool in decision-making.

CONCLUSIONS

Localized RCC requires highly nuanced treatment decision-making, balancing patient- and tumor-specific clinical variables against indirect structural influences to provide optimal patient care.

PATIENT SUMMARY

With expanding treatment options for localized kidney cancer, treatment decision is highly nuanced and requires shared decision-making. Patient decision aids may be helpful in the treatment discussion.

摘要

背景

随着主动监测和热消融(TA)的加入,泌尿科医生将部分(PN)和根治性肾切除术(RN)作为局限性肾细胞癌(RCC)的一线治疗选择,适当的治疗决策变得越来越复杂。

目的

批判性地回顾局限性、非复发性 RCC 的治疗选择;强调影响治疗决策的患者、肾功能、肿瘤和提供者因素;并提供一个概念化决策过程的框架。

证据获取

对医学文献进行了合作的批判性回顾。

证据综合

我们确定了管理局限性 RCC 的三个关键决策点:(1)监测与治疗的决策,(2)治疗方式(TA、PN 或 RN)的决策,(3)手术方法(开放与微创)的决策。在评估影响这些治疗决策的因素时,我们详细阐述了直接或间接影响每个决策点的患者、肾功能、肿瘤和提供者因素。由于当前基于预选患者数据集的列线图在前瞻性环境中的表现不佳,因此应谨慎使用这些工具。患者决策辅助工具在决策制定中未得到充分利用。

结论

局限性 RCC 需要高度复杂的治疗决策,需要平衡患者和肿瘤特定的临床变量与间接结构影响,以提供最佳的患者护理。

患者总结

随着局限性肾癌治疗选择的扩大,治疗决策非常复杂,需要共同决策。患者决策辅助工具可能有助于治疗讨论。

相似文献

1
Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass.协作综述:影响局限性肾实体瘤患者治疗决策的因素。
Eur Urol. 2021 Nov;80(5):575-588. doi: 10.1016/j.eururo.2021.01.021. Epub 2021 Feb 6.
2
Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses.解剖复杂肾肿瘤的部分和根治性肾切除术风险获益权衡的协作评估。
Eur Urol. 2017 Jul;72(1):64-75. doi: 10.1016/j.eururo.2016.11.038. Epub 2016 Dec 14.
3
A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer.对肾癌微创手术和主动监测实际作用的批判性分析。
Eur Urol. 2010 Feb;57(2):223-32. doi: 10.1016/j.eururo.2009.10.023. Epub 2009 Oct 20.
4
How Does Treatment Uncertainty Factor into Decisions to Place Patients on Active Surveillance for Kidney Cancer?治疗的不确定性如何影响将患者置于肾癌主动监测的决策?
Eur Urol Focus. 2019 Nov;5(6):946-948. doi: 10.1016/j.euf.2019.07.002. Epub 2019 Jul 25.
5
Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study.T1a 期肾细胞癌的热消融、手术切除与主动监测的疗效比较:监测、流行病学和最终结果(SEER)-医疗保险关联人群研究。
Radiology. 2018 Jul;288(1):81-90. doi: 10.1148/radiol.2018171407. Epub 2018 May 8.
6
Does renal mass biopsy influence multidisciplinary treatment recommendations?肾肿瘤活组织检查是否会影响多学科治疗建议?
Scand J Urol. 2020 Feb;54(1):27-32. doi: 10.1080/21681805.2019.1703805. Epub 2019 Dec 23.
7
Renal Mass and Localized Renal Cancer: AUA Guideline.肾脏肿块和局限性肾细胞癌:AUA 指南。
J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.
8
Treatment of localised renal cell carcinoma.局限性肾细胞癌的治疗。
Eur Urol. 2011 Oct;60(4):662-72. doi: 10.1016/j.eururo.2011.06.040. Epub 2011 Jun 29.
9
Frailty predicts outcome of partial nephrectomy and guides treatment decision towards active surveillance and tumor ablation.衰弱预测部分肾切除术的结果,并指导治疗决策向主动监测和肿瘤消融倾斜。
World J Urol. 2021 Aug;39(8):2843-2851. doi: 10.1007/s00345-020-03556-7. Epub 2021 Jan 30.
10
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.部分肾切除术与根治性肾切除术治疗 T1b 和 T2 期临床肾肿瘤的比较:系统评价和荟萃分析。
Eur Urol. 2017 Apr;71(4):606-617. doi: 10.1016/j.eururo.2016.08.060. Epub 2016 Sep 7.

引用本文的文献

1
Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.经皮消融术在肾肿瘤中的当前应用:德国介入放射学和微创治疗学会登记处的分析
Eur Radiol. 2025 Mar;35(3):1723-1731. doi: 10.1007/s00330-024-11343-w. Epub 2025 Feb 28.
2
'BJUI Clinical Dilemma': the incidental small renal mass in a solitary kidney.《英国泌尿学杂志》临床困境:孤立肾中的偶然发现的小肾肿块
BJU Int. 2025 Mar;135(3):371-379. doi: 10.1111/bju.16627. Epub 2025 Jan 6.
3
Surgical Experience and Functional Outcomes after Laparoscopic and Robot-Assisted Partial Nephrectomy: Results from a Multi-Institutional Collaboration.
腹腔镜和机器人辅助部分肾切除术后的手术经验及功能结果:一项多机构合作的结果
J Clin Med. 2024 Oct 9;13(19):6016. doi: 10.3390/jcm13196016.
4
Outcomes of open versus robotic partial nephrectomy: a 20-year single institution experience.开放手术与机器人辅助部分肾切除术的结果比较:20 年单中心经验。
J Robot Surg. 2024 Aug 8;18(1):315. doi: 10.1007/s11701-024-02027-0.
5
Same Organ, Two Cancers: Complete Analysis of Renal Cell Carcinomas and Upper Tract Urothelial Carcinomas.同一器官,两种癌症:肾细胞癌和上尿路尿路上皮癌的全面分析。
Medicina (Kaunas). 2024 Jul 12;60(7):1126. doi: 10.3390/medicina60071126.
6
Predicting EGFR Status After Radical Nephrectomy or Partial Nephrectomy for Renal Cell Carcinoma on CT Using a Self-attention-based Model: Variable Vision Transformer (vViT).使用基于自注意力的模型可变视觉变换器(vViT)在CT上预测肾细胞癌根治性肾切除或部分肾切除术后的表皮生长因子受体(EGFR)状态
J Imaging Inform Med. 2024 Dec;37(6):3057-3069. doi: 10.1007/s10278-024-01180-0. Epub 2024 Jun 28.
7
Decisional Conflict Among Patients Newly Diagnosed With Clinical T1 Renal Masses: A Prospective Study.初诊为临床 T1 期肾肿瘤患者的决策冲突:一项前瞻性研究。
J Urol. 2024 Aug;212(2):320-330. doi: 10.1097/JU.0000000000004023. Epub 2024 May 8.
8
The evolving management of small renal masses.小肾肿瘤的不断演变的治疗策略。
Nat Rev Urol. 2024 Jul;21(7):406-421. doi: 10.1038/s41585-023-00848-6. Epub 2024 Feb 16.
9
Near-Infrared Fluorescence Imaging with Indocyanine Green for Robot-Assisted Partial Nephrectomy: A Systematic Review and Meta-Analysis.吲哚菁绿近红外荧光成像在机器人辅助部分肾切除术中的应用:系统评价与Meta分析
Cancers (Basel). 2023 Nov 24;15(23):5560. doi: 10.3390/cancers15235560.
10
Adding Stereotactic Radiation to the Multidisciplinary Armamentarium for Localized Renal Cell Carcinoma: Ready for Primetime? : An Editorial Regarding a Recent 5-Year Efficacy and Safety Report of a Multicenter Cohort of Primary RCC Patients Treated with SABR.将立体定向放射治疗纳入局限性肾细胞癌多学科治疗手段:时机已到?:关于一项原发性肾细胞癌患者多中心队列接受立体定向体部放射治疗的近期5年疗效与安全性报告的述评
Ann Surg Oncol. 2023 Nov;30(12):6947-6949. doi: 10.1245/s10434-023-13755-2. Epub 2023 Jun 19.